C86.41
C86.41 — Blastic NK-cell lymphoma, in remission
Billable / specific codeICD-10-CM
C86.41 is a billable, specific ICD-10-CM code for blastic nk-cell lymphoma, in remission. It is valid for submission on a claim.
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN), in remission
Risk adjustment
C86.41 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 19 Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers1.798 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C86.41 is named in 30 Medicare coverage policies — 30 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C86.4. If C86.41 is not quite right, the correct code is usually one of these.
Questions about C86.41
- Is C86.41 a billable ICD-10-CM code?
- Yes. C86.41 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C86.41 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).